

Maria C Cid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4660023/publications.pdf>

Version: 2024-02-01

166
papers

20,167
citations

21215

62
h-index

12272

138
g-index

175
all docs

175
docs citations

175
times ranked

13209
citing authors

#	ARTICLE	IF	CITATIONS
1	2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis and Rheumatism, 2013, 65, 1-11.	6.7	4,839
2	Trial of Tocilizumab in Giant-Cell Arteritis. New England Journal of Medicine, 2017, 377, 317-328.	13.9	974
3	EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 310-317.	0.5	889
4	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine, 2017, 376, 1921-1932.	13.9	682
5	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2020, 79, 19-30.	0.5	667
6	EULAR recommendations for the management of large vessel vasculitis. Annals of the Rheumatic Diseases, 2009, 68, 318-323.	0.5	596
7	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. Annals of Internal Medicine, 2007, 146, 621.	2.0	491
8	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis and Rheumatism, 2002, 46, 1309-1318.	6.7	480
9	The cryoglobulinaemias. Lancet, The, 2012, 379, 348-360.	6.3	460
10	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2012, 71, 484-492.	0.5	451
11	Estrogen Promotes Angiogenic Activity in Human Umbilical Vein Endothelial Cells In Vitro and in a Murine Model. Circulation, 1995, 91, 755-763.	1.6	382
12	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Annals of the Rheumatic Diseases, 2008, 67, 1004-1010.	0.5	343
13	Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Annals of the Rheumatic Diseases, 2012, 71, 1170-1176.	0.5	300
14	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
15	Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis and Rheumatism, 1998, 41, 26-32.	6.7	255
16	Tissue production of pro-inflammatory cytokines (IL-1, TNF and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. British Journal of Rheumatology, 2003, 43, 294-301.	2.5	237
17	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.5	220
18	Diagnosis and classification of polyarteritis nodosa. Journal of Autoimmunity, 2014, 48-49, 84-89.	3.0	189

#	ARTICLE	IF	CITATIONS
19	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	3.3	182
20	Fibronectin Upregulates Gelatinase B (MMP-9) and Induces Coordinated Expression of Gelatinase A (MMP-2) and Its Activator MT1-MMP (MMP-14) by Human T Lymphocyte Cell Lines. A Process Repressed Through RAS/MAP Kinase Signaling Pathways. <i>Blood</i> , 1999, 94, 2754-2766.	0.6	177
21	Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. <i>Arthritis and Rheumatism</i> , 2008, 59, 422-430.	6.7	174
22	Expression of an Estrogen Receptor by Human Coronary Artery and Umbilical Vein Endothelial Cells. <i>Circulation</i> , 1996, 94, 1402-1407.	1.6	172
23	Elevated Production of Interleukin-6 Is Associated With a Lower Incidence of Disease-Related Ischemic Events in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2003, 107, 2428-2434.	1.6	169
24	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.5	165
25	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. <i>Nature Communications</i> , 2019, 10, 5120.	5.8	160
26	Relapses in Patients With Giant Cell Arteritis. <i>Medicine (United States)</i> , 2014, 93, 194-201.	0.4	158
27	Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1388-1392.	0.5	148
28	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	2.9	146
29	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
30	Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2938-2943.	1.8	141
31	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139
32	Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1636-1641.	6.7	137
33	Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: Inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. <i>Arthritis and Rheumatism</i> , 2000, 43, 184-194.	6.7	128
34	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
35	A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 47, 29-35.	6.7	127
36	Estrogens and the Vascular Endothelium. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 143-157.	1.8	120

#	ARTICLE	IF	CITATIONS
37	Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. <i>Arthritis and Rheumatism</i> , 2001, 44, 1387-1395.	6.7	105
38	Treatment of Polymyalgia Rheumatica. <i>Archives of Internal Medicine</i> , 2009, 169, 1839.	4.3	104
39	Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1826-1832.	0.5	103
40	Extramedullary multiple myeloma escapes the effect of thalidomide. <i>Haematologica</i> , 2004, 89, 832-6.	1.7	100
41	Tissue and Serum Angiogenic Activity Is Associated With Low Prevalence of Ischemic Complications in Patients With Giant-Cell Arteritis. <i>Circulation</i> , 2002, 106, 1664-1671.	1.6	99
42	Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 575-583.e1.	2.4	99
43	Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study. <i>Rheumatology</i> , 2011, 50, 2061-2070.	0.9	97
44	Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1481-1487.	0.5	96
45	SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. <i>Blood</i> , 2014, 124, 2235-2247.	0.6	94
46	SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. <i>Blood</i> , 2017, 130, 501-513.	0.6	90
47	Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia. <i>Arthritis and Rheumatism</i> , 2012, 64, 854-865.	6.7	89
48	Blocking interferon β reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1177-1186.	0.5	89
49	Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. <i>Journal of Pathology</i> , 2004, 204, 311-316.	2.1	88
50	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82
51	Large vessel vasculitides. <i>Current Opinion in Rheumatology</i> , 1998, 10, 18-28.	2.0	78
52	Effect of Glucocorticoid Treatment on Computed Tomography Angiography Detected Large-Vessel Inflammation in Giant-Cell Arteritis. A Prospective, Longitudinal Study. <i>Medicine (United States)</i> , 2015, 94, e486.	0.4	78
53	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
54	Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 295-306.	2.9	78

#	ARTICLE	IF	CITATIONS
55	Gelatinase expression and proteolytic activity in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1429-1435.	0.5	76
56	Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor $\hat{I}\pm$ and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Research, 2010, 62, 835-841.	1.5	75
57	Glucocorticoid Dosages and Acuteâ€Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. <i>Arthritis and Rheumatology</i> , 2019, 71, 1329-1338.	2.9	74
58	Large-vessel vasculitis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 93.	18.1	74
59	Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1581-1588.	0.5	71
60	Life-Threatening Cryoglobulinemic Patients With Hepatitis C. <i>Medicine (United States)</i> , 2013, 92, 273-284.	0.4	69
61	Interferon- γ may exacerbate cryoglobulinemia-related ischemic manifestations: An adverse effect potentially related to its anti-angiogenic activity. <i>Arthritis and Rheumatism</i> , 1999, 42, 1051-1055.	6.7	68
62	Changes in biomarkers after therapeutic intervention in temporal arteries cultured in Matrigel: a new model for preclinical studies in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 616-623.	0.5	68
63	Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1994, 37, 1055-1061.	6.7	67
64	Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1624-1634.	0.5	67
65	Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis*. <i>Rheumatology</i> , 2006, 45, 1356-1363.	0.9	64
66	Central Nervous System Vasculitis: Still More Questions than Answers. <i>Current Neuropharmacology</i> , 2011, 9, 437-448.	1.4	64
67	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	1.0	64
68	Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. <i>Autoimmunity Reviews</i> , 2016, 15, 9-15.	2.5	62
69	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	1.6	62
70	Increased expression of the endothelin system in arterial lesions from patients with giant-cell arteritis: association between elevated plasma endothelin levels and the development of ischaemic events. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 434-442.	0.5	59
71	Dynamic pattern of endothelial cell adhesion molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. <i>Arthritis and Rheumatism</i> , 1998, 41, 435-444.	6.7	56
72	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56

#	ARTICLE	IF	CITATIONS
73	Membrane Attack Complex Deposits in Cutaneous Lesions of Dermatomyositis. <i>Archives of Dermatology</i> , 1995, 131, 1386.	1.7	55
74	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , 2016, 95, e2368.	0.4	55
75	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	1.6	52
76	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.	2.2	52
77	New developments in the pathogenesis of systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 1996, 8, 1-11.	2.0	51
78	Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1882-1886.	0.5	51
79	Signaling through CD50 (ICAM-3) stimulates T lymphocyte binding to human umbilical vein endothelial cells and extracellular matrix proteins via an increase in β 1 and β 2 integrin function. <i>European Journal of Immunology</i> , 1994, 24, 1377-1382.	1.6	50
80	Imaging in systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 53-62.	2.0	49
81	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.5	49
82	Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2004, 51, 674-678.	6.7	48
83	Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. <i>Rheumatology</i> , 2020, 59, 1574-1580.	0.9	47
84	Dual function of focal adhesion kinase in regulating integrin-induced MMP2 and MMP9 release by human T lymphoid cells. <i>FASEB Journal</i> , 2005, 19, 1875-1877.	0.2	46
85	The spectrum of vascular involvement in giant cell arteritis: clinical consequences of detrimental vascular remodelling at different sites. <i>Apmis</i> , 2009, 117, 10-20.	0.9	44
86	Identification of IL-23p19 as an endothelial proinflammatory peptide that promotes gp130-STAT3 signaling. <i>Science Signaling</i> , 2016, 9, ra28.	1.6	44
87	Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis. <i>Current Rheumatology Reports</i> , 2004, 6, 184-194.	2.1	43
88	Urologic and male genital manifestations of granulomatosis with polyangiitis. <i>Autoimmunity Reviews</i> , 2015, 14, 897-902.	2.5	43
89	Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. <i>Cytokine</i> , 2008, 41, 244-253.	1.4	41
90	Development of Ischemic Complications in Patients With Giant Cell Arteritis Presenting With Apparently Isolated Polymyalgia Rheumatica. <i>Medicine (United States)</i> , 2007, 86, 233-241.	0.4	38

#	ARTICLE	IF	CITATIONS
91	Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA—a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. <i>Rheumatology</i> , 2012, 51, 841-851.	0.9	38
92	OESTROGEN AND ENDOTHELIAL CELL ANGIOGENIC ACTIVITY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 1996, 23, 247-250.	0.9	36
93	Influence of the IL17A locus in giant cell arteritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1742-1745.	0.5	36
94	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 819-825.	6.7	35
95	Estradiol enhances endothelial cell interactions with extracellular matrix proteins via an increase in integrin expression and function. <i>Angiogenesis</i> , 1999, 3, 271-280.	3.7	34
96	Response to thalidomide in multiple myeloma: impact of angiogenic factors. <i>Cytokine</i> , 2004, 26, 145-148.	1.4	34
97	Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients. <i>RMD Open</i> , 2017, 3, e000570.	1.8	33
98	Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways. <i>Frontiers in Immunology</i> , 2018, 9, 809.	2.2	33
99	Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved. <i>Rheumatology</i> , 2018, 57, ii51-ii62.	0.9	32
100	The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. <i>Leukemia</i> , 2021, 35, 2635-2649.	3.3	32
101	The Expanding Role of Imaging in Systemic Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 733-751.	0.8	30
102	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018, 50, 12-19.	1.0	30
103	Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 772-777.	1.6	28
104	Five Clinical Conundrums in the Management of Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 819-834.	0.8	26
105	Blocking GM-CSF receptor $\hat{\pm}$ with mavrimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 524-536.	0.5	26
106	Characterization of isolated retinal vasculitis. Analysis of a cohort from a single center and literature review. <i>Autoimmunity Reviews</i> , 2017, 16, 237-243.	2.5	25
107	The COVID-19 pandemic and ANCA-associated vasculitis “ reports from the EUVAS meeting and EUVAS education forum. <i>Autoimmunity Reviews</i> , 2021, 20, 102986.	2.5	25
108	B55 $\hat{\pm}$ /PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling. <i>Circulation Research</i> , 2020, 127, 707-723.	2.0	24

#	ARTICLE	IF	CITATIONS
109	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	0.9	24
110	Giant-Cell Arteritis Presenting with Ipsilateral Hemiplegia and Lateral Medullary Syndrome. <i>European Neurology</i> , 1989, 29, 266-268.	0.6	23
111	Endothelial Cell Activation in Muscle Biopsy Samples Is Related to Clinical Severity in Human Cerebral Malaria. <i>Journal of Infectious Diseases</i> , 1999, 179, 475-483.	1.9	23
112	Evidence of association of the <i>NLRP1</i> gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.	0.5	23
113	PI3K γ inhibition reshapes follicular lymphoma's immune microenvironment cross talk and unleashes the activity of venetoclax. <i>Blood Advances</i> , 2020, 4, 4217-4231.	2.5	23
114	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
115	Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1684-1687.e10.	1.5	22
116	Recurrent Arterial Thrombosis in a Patient with Giant-cell Arteritis and Raised Anticardiolipin Antibody Levels. <i>Rheumatology</i> , 1988, 27, 164-165.	0.9	21
117	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.4	21
118	Endothelial cell biology, perivascular inflammation, and vasculitis.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, SII45-SII45.	0.6	21
119	Methylome and transcriptome profiling of giant cell arteritis monocytes reveals novel pathways involved in disease pathogenesis and molecular response to glucocorticoids. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1290-1300.	0.5	20
120	Sustained spontaneous clinical remission in giant cell arteritis: Report of two cases with long-term followup. <i>Arthritis and Rheumatism</i> , 2006, 55, 160-162.	6.7	17
121	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	1.1	17
122	Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. <i>Haematologica</i> , 2010, 95, 456-463.	1.7	16
123	Advances in the Diagnosis of Large Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 125-140.	0.8	15
124	Tissue targeting and disease patterns in systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 259-279.	1.4	13
125	Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. <i>European Journal of Internal Medicine</i> , 2022, 95, 61-66.	1.0	12
126	Early improvement of radiological signs of large-vessel inflammation in giant cell arteritis upon glucocorticoid treatment. <i>Rheumatology</i> , 2013, 52, 1335-1336.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies. <i>Rheumatology</i> , 2020, 59, iii17-iii27.	0.9	9
128	Stimulatory Autoantibodies to the PDGF Receptor in Scleroderma. <i>New England Journal of Medicine</i> , 2006, 355, 1278-1280.	13.9	8
129	THU0008â€¦GM-CSF PATHWAY SIGNATURE IDENTIFIED IN TEMPORAL ARTERY BIOPSIES OF PATIENTS WITH GIANT CELL ARTERITIS. , 2019, , .		8
130	Prevalence of cardiovascular risk factors, the use of statins and of aspirin in Takayasu Arteritis. <i>Scientific Reports</i> , 2021, 11, 14404.	1.6	8
131	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. <i>Autoimmunity Reviews</i> , 2022, 21, 103034.	2.5	8
132	Treatment of Large Vessel Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 435-442.	1.2	7
133	Identification of a shared genetic risk locus for Kawasaki disease and immunoglobulin A vasculitis by a cross-phenotype meta-analysis. <i>Rheumatology</i> , 2022, 61, 1204-1210.	0.9	7
134	T-cell population of primary and secondary cutaneous B-cell lymphomas does not express the cutaneous lymphocyte-associated antigen (CLA). <i>Archives of Dermatological Research</i> , 1997, 289, 327-330.	1.1	5
135	3. Pathogenesis of giant cell arteritis. <i>Rheumatology</i> , 2014, 53, i2-i3.	0.9	5
136	Preparation of Endothelial Cells. <i>Current Protocols in Cell Biology</i> , 1998, 00, Unit 2.3.	2.3	4
137	The Search for Genetic Links in ANCA-Associated Vasculitis and Its Variants. <i>New England Journal of Medicine</i> , 2012, 367, 271-273.	13.9	4
138	Evaluation of Aortic Inflammation Using Computed Tomographic Angiography: Vasculitis, Atherosclerosis, or Both. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 415-416.	1.3	3
139	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , 2018, 13, e0209343.	1.1	3
140	Utilidad de las t�cnicas de imagen en la valoraci3n de la arteritis de c�lulas gigantes. <i>Medicina Cl�nica</i> , 2019, 152, 495-501.	0.3	3
141	Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome. <i>Frontiers in Immunology</i> , 2022, 13, 840974.	2.2	3
142	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. <i>Kidney International Reports</i> , 2022, 7, 1745-1757.	0.4	3
143	Systemic vasculitis: still a long and winding road. <i>Current Opinion in Rheumatology</i> , 2008, 20, 1-2.	2.0	2
144	Small�vessel vasculitis surrounding an uninflamed temporal artery as a diagnostic criterion for polymyalgia rheumatica: Comment on the article by Chatelain et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 2853-2854.	6.7	2

#	ARTICLE	IF	CITATIONS
145	B lymphocytes may play a significant role in large-vessel vasculitis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 475-477.	0.3	2
146	Sustained Remission: An Unmet Need in Patients with Giant-cell Arteritis. <i>Journal of Rheumatology</i> , 2015, 42, 1081-1082.	1.0	2
147	FRI0487â€¦UTILITY OF TRABECULAR BONE SCORE(TBS) FOR FRACTURE RISK ASSESSMENT IN GLUCOCORTICOID-INDUCED OSTEOPOROSIS. , 2019, , .		2
148	THU0286â€¦MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
149	Malignant histiocytosis as a fatal complication of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1991, 34, 1557-1559.	6.7	1
150	Functionally Relevant Treg Cells Are Present in Giant Cell Arteritis Lesions: Comment on the Article by Samson et al. <i>Arthritis and Rheumatism</i> , 2013, 65, 1133-1134.	6.7	1
151	Scalp Necrosis in Giant Cell Arteritis. <i>Mayo Clinic Proceedings</i> , 2014, 89, e99.	1.4	1
152	FRI0284â€¦RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
153	An 80-year-old man with headache, orbital pain and elevated ESR: challenges in the diagnosis of a patient with suspected giant cell arteritis. <i>Rheumatology</i> , 2021, 60, iii12-iii14.	0.9	1
154	How Is Infliximab Harmful?. <i>Annals of Internal Medicine</i> , 2008, 148, 166.	2.0	1
155	HIV-associated vasculitis. Part II: histologic and angiographic diagnostic reconfirmation after an uncontrolled HIV infection and fatal outcome. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 151-152.	0.4	1
156	Type 1 autoimmune hepatitis in a patient with microscopic polyangiitis: challenges in diagnosis and treatment. <i>Medicina Clínica</i> , 2011, 136, 345-348.	0.3	0
157	Authorsâ€™ response to the eLetter by Moiseev et al. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, e71-e71.	0.5	0
158	New insights into the molecular basis of systemic vasculitis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 323-324.	3.5	0
159	Diagnostic clues for giant cell arteritis: Beyond headache and ischemic optic neuritis. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 380-381.	0.1	0
160	A very late presentation of polymyalgia rheumatica in a patient with giant cell arteritis: recurrence or casual association?. <i>Modern Rheumatology Case Reports</i> , 2019, 3, 130-133.	0.3	0
161	Usefulness of imaging techniques in the management of giant cell arteritis. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.784314 rgBT /Overl	0.1	0
162	185.â€¦GENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
163	SP0073â€¦DIAGNOSIS OF GASTROINTESTINAL VASCULITIS. , 2019, , .		0
164	FRIO466â€¦RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF FRACTURES IN GLUCOCORTICOID TREATED PATIENTS. THE ROLE OF HYPOGONADISM. , 2019, , .		0
165	Risks and benefits of tocilizumab monotherapy in giant cell arteritis. Lancet Rheumatology, The, 2021, 3, e606-e607.	2.2	0
166	Occlusive vasculopathy in human immunodeficiency virus (HIV)-associated vasculitis: unusual clinical and imaging course. Clinical and Experimental Rheumatology, 2017, 35 Suppl 103, 185-188.	0.4	0